DRESS/DiHS syndrome induced by Propylthiouracil: a case report.
Drug reaction with eosinophilia and systemic symptoms (DRESS)
Drug-induced hypersensitivity syndrome (DiHS)
Propylthiouracil
Journal
BMC endocrine disorders
ISSN: 1472-6823
Titre abrégé: BMC Endocr Disord
Pays: England
ID NLM: 101088676
Informations de publication
Date de publication:
23 Jan 2023
23 Jan 2023
Historique:
received:
09
03
2022
accepted:
16
01
2023
entrez:
23
1
2023
pubmed:
24
1
2023
medline:
26
1
2023
Statut:
epublish
Résumé
Drug reaction with eosinophilia and systemic symptoms (DRESS), also known as Drug-induced hypersensitivity syndrome (DiHS), is a severe adverse drug reaction. Propylthiouracil, a member of thiouracils group, is widely used in medical treatment of hyperthyroidism. Propylthiouracil is associated with multiple adverse effects such as rash, agranulocytosis hepatitis and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, but rarely triggers DRESS/DiHS syndrome. Here, we describe a severe case of propylthiouracil-induced DRESS/DiHS syndrome. A 38-year-old female was treated with methimazole for hyperthyroidism at first. 4 weeks later, the patient developed elevated liver transaminase so methimazole was stopped. After liver function improved in 2 weeks, medication was switched to propylthiouracil therapy. The patient subsequently developed nausea and rash followed by a high fever, acute toxic hepatitis and multiple organ dysfunction (liver, lung and heart), which lasted for 1 month after propylthiouracil was started. According to the diagnostic criteria, the patient was diagnosed of DRESS/DiHS syndrome which was induced by propylthiouracil. As a result, propylthiouracil was immediately withdrawn. And patient was then treated with adalimumab, systematic corticosteroids and plasmapheresis in sequence. Symptoms were finally resolved 4 weeks later. Propylthiouracil is a rare cause of the DRESS/DiHS syndrome, which typically consists of severe dermatitis and various degrees of internal organ involvement. We want to emphasize through this severe case that DRESS/DiHS syndrome should be promptly recognized to hasten recovery.
Sections du résumé
BACKGROUND
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS), also known as Drug-induced hypersensitivity syndrome (DiHS), is a severe adverse drug reaction. Propylthiouracil, a member of thiouracils group, is widely used in medical treatment of hyperthyroidism. Propylthiouracil is associated with multiple adverse effects such as rash, agranulocytosis hepatitis and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, but rarely triggers DRESS/DiHS syndrome. Here, we describe a severe case of propylthiouracil-induced DRESS/DiHS syndrome.
CASE PRESENTATION
METHODS
A 38-year-old female was treated with methimazole for hyperthyroidism at first. 4 weeks later, the patient developed elevated liver transaminase so methimazole was stopped. After liver function improved in 2 weeks, medication was switched to propylthiouracil therapy. The patient subsequently developed nausea and rash followed by a high fever, acute toxic hepatitis and multiple organ dysfunction (liver, lung and heart), which lasted for 1 month after propylthiouracil was started. According to the diagnostic criteria, the patient was diagnosed of DRESS/DiHS syndrome which was induced by propylthiouracil. As a result, propylthiouracil was immediately withdrawn. And patient was then treated with adalimumab, systematic corticosteroids and plasmapheresis in sequence. Symptoms were finally resolved 4 weeks later.
CONCLUSIONS
CONCLUSIONS
Propylthiouracil is a rare cause of the DRESS/DiHS syndrome, which typically consists of severe dermatitis and various degrees of internal organ involvement. We want to emphasize through this severe case that DRESS/DiHS syndrome should be promptly recognized to hasten recovery.
Identifiants
pubmed: 36691013
doi: 10.1186/s12902-023-01273-x
pii: 10.1186/s12902-023-01273-x
pmc: PMC9869506
doi:
Substances chimiques
Propylthiouracil
721M9407IY
Methimazole
554Z48XN5E
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
22Subventions
Organisme : National Natural Science Foundation of China
ID : 81900714
Organisme : Suzhou Municipal Science and Technology Bureau
ID : SYSD126
Informations de copyright
© 2023. The Author(s).
Références
JAMA Dermatol. 2016 Nov 1;152(11):1254-1257
pubmed: 27438540
Horm Res. 1991;35(3-4):132-6
pubmed: 1806466
Asian Pac J Allergy Immunol. 2022 Dec;40(4):418-421
pubmed: 32170921
Cytokine. 2019 Apr;116:128-133
pubmed: 30711852
Br J Dermatol. 2013 Nov;169(5):1071-80
pubmed: 23855313
J Dermatol. 2015 Mar;42(3):276-82
pubmed: 25623158
Am J Kidney Dis. 2010 Mar;55(3):e11-4
pubmed: 20110143
Allergol Int. 2019 Jul;68(3):301-308
pubmed: 31000444
Cutis. 2018 Nov;102(5):322-326
pubmed: 30566546
Allergy. 2010 Mar;65(3):407-9
pubmed: 19796191
Turk J Pediatr. 2006 Apr-Jun;48(2):162-5
pubmed: 16848120
Int J Endocrinol. 2019 Oct 03;2019:7959615
pubmed: 31687021
Sci Rep. 2015 Apr 23;5:9913
pubmed: 25905582
Drug Saf. 2019 Aug;42(8):973-992
pubmed: 31020549
Semin Cutan Med Surg. 1996 Dec;15(4):250-7
pubmed: 9069593
Arch Dermatol. 2012 Apr;148(4):543-4
pubmed: 22508885
JAMA Dermatol. 2020 Jun 1;156(6):704-706
pubmed: 32159726
Arch Dermatol. 1998 Sep;134(9):1108-12
pubmed: 9762023
Int J Mol Sci. 2021 Feb 21;22(4):
pubmed: 33670052
Expert Opin Drug Saf. 2017 Feb;16(2):139-147
pubmed: 27936971
HLA. 2017 Dec;90(6):335-342
pubmed: 28884973
J Am Acad Dermatol. 2015 Feb;72(2):246-52
pubmed: 25592341
JAAD Case Rep. 2017 Jul 18;3(4):332-335
pubmed: 28752124
Dermatology. 2003;206(4):353-6
pubmed: 12771485
J Investig Allergol Clin Immunol. 2020;30(4):229-253
pubmed: 31932268
Sci Transl Med. 2010 Aug 25;2(46):46ra62
pubmed: 20739682
Endocr Pract. 2020 Feb;26(2):207-217
pubmed: 31652102
Thyroid. 2016 Oct;26(10):1343-1421
pubmed: 27521067
J Am Acad Dermatol. 2013 May;68(5):709.e1-9; quiz 718-20
pubmed: 23602183
Int J Mol Sci. 2017 Jun 09;18(6):
pubmed: 28598363
Int Arch Occup Environ Health. 2019 Apr;92(3):395-401
pubmed: 30758654
Am J Med. 2012 Jul;125(7):e9-10
pubmed: 22727240
J Am Acad Dermatol. 2019 Mar;80(3):670-678.e2
pubmed: 30240780